Company intelligence / Profile preview
CytoVac
Hørsholm, N/A, Denmarkcytovac.com ↗
- Ownership
- Private
- Employees
- ~49
- Development stage
- Phase 1
01
Overview
CytoVac has developed the ALECSAT platform—a cell-based immunotherapy using a patient’s own activated immune cells to target tumors. The approach aims to minimize side effects compared to traditional therapies. The company has reported promising preclinical and early clinical results but discontinued its glioblastoma program; further development appears focused on next-generation products targeting other cancers such as breast cancer
- Therapeutic areas
- Oncology
- Modalities
- Cell therapy (autologous activated immune cells)immunotherapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on CytoVac.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CytoVac.